Deals In Depth: December 2011
Janssen paid $150 million for Pharmacyclics’ Phase II Btk inhibitor, 2011’s largest up-front for a single asset. Alexion acquired rare disease developer Enobia for just over $1 billion in up-front and earn-out payments. Biopharma fundraising dipped in December, while device financing increased for the second month in a row.
You may also be interested in...
Sue Nabi’s success at L’Oreal, where she headed the firm’s global L’Oreal Paris and Lancome businesses, her skin-care savvy as founder of the luxury, “clean, green and vegan” Orveda, and her experience as a career champion of diversity were major draws for Coty, where she begins as CEO on 1 September.
Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.